A carregar...
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia
The successful use of PARP1 inhibitors like olaparib (Loparza(®)) in the treatment of BRCA1/2- deficient breast cancer has provided clinical proof of concept for applying personalized medicine based on synthetic lethality to the treatment of cancer. Unfortunately, all marketed PARP1 inhibitors act b...
Na minha lista:
| Publicado no: | Med Chem Res |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7560981/ https://ncbi.nlm.nih.gov/pubmed/33071527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00044-020-02537-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|